---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-026302"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2024-02-22T23:59:59+00:00"
generated_at: "2026-06-05T20:44:28.410117+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics CFO C. Evan Ballantyne resigns; Gianluca Fuggetta appointed Principal Financial Officer

## Summary
- CFO C. Evan Ballantyne resigns effective March 1, 2024, departing all positions.
- Gianluca Fuggetta, current Senior Director, appointed VP of Finance and Principal Financial Officer from March 1.
- Company has initiated a search to identify a new Chief Financial Officer.
- Fuggetta previously served as Assurance Manager at PwC; joined Gain in July 2022.
- No family relationships or arrangements exist in connection with his appointment.

## SEC filing metadata
- accession: 0001104659-24-026302
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2024-02-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465924026302/0001104659-24-026302-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465924026302/tm245020d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-026302
- JSON: https://secwatch.observer/filing/0001104659-24-026302.json
- Plain text: https://secwatch.observer/filing/0001104659-24-026302.txt

## Key facts
- Executive change
  C. Evan Ballantyne resigned as Chief Financial Officer at Gain Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On February 19, 2024, Gain Therapeutics, Inc. (the “Company”) received notice of the resignation of C. Evan Ballantyne as the Company’s Chief Financial Officer, and all other positions held at the Company, to be effective March 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465924026302/0001104659-24-026302-index.htm
- Executive change
  Gianluca Fuggetta was appointed as Vice President of Finance, Principal Financial Officer at Gain Therapeutics, Inc..
  - Action: appointed
  - Role: Vice President of Finance, Principal Financial Officer
  source text: On February 21, 2024, the Board of Directors of the Company appointed Gianluca Fuggetta, the Company’s current Senior Director, Finance & Corporate Reporting and Principal Accounting Officer, as the Company’s Vice President of Finance and to also serve as the Company’s Principal Financial Officer, to be effective March 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000110465924026302/0001104659-24-026302-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.